- Home
- INO
INO
Inovio Pharmaceuticals Inc.
as 04-24-2025 4:00pm EST
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | N/A | IPO Year: | 1998 |
| Target Price: | $12.20 | AVG Volume (30 days): | 686.6K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $13.44 | Next Earning Date: | 05-12-2025 |
| Revenue: | $217,756 | Revenue Growth: | -73.83% |
| Revenue Growth (this year): | 1308.92% | Revenue Growth (next year): | 611.08% |
Latest Inovio Pharmaceuticals Inc. News
INO Breaking Stock News: Dive into INO Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Bet on These 5 Top-Ranked Stocks With Rising P/E
Zacks
15 days ago
Inovio (INO) Upgraded to Buy: Here's What You Should Know
PR Newswire
16 days ago
INOVIO to Present at Upcoming Scientific Conferences
Zacks
24 days ago
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
MT Newswires
a month ago
RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Keeps Sector Perform, Speculative Risk
GuruFocus.com
a month ago
Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Motley Fool
a month ago
Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript
PR Newswire
a month ago
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Compare INO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INO Inovio Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.